| | pro-SP-B | pro-SP-C |
|---|
Detecting antibody | CTERMB | CFLANK | NFLANK | NFPROX | NPROSP-C-C2 |
|---|
Mr of bands (kDa) | | | | | |
|---|
40–42 | 57%* [2,5–7] | 14% [7] | - | - | - |
25–26 | 71% [2,3,5–7] | 38%+ [4,6,7] | 57% [2,4,5,6] | - | - |
19–21 | - | - | 14% [6] | 14%§ [6] | - |
15 | - | - | - | 29%§ [2,7] | - |
9 | 14% [6] | 14% [7] | - | - | 14% [6] |
3.6 | - | - | - | 14%§ [3] | - |
- Percent of subjects with bands and identification numbers of those subjects in whom bands reacting with the anti-pro-SP-B-antibodies CTERMB, NFLANK, CFLANK, NFPROX and displaced by the CTERMB, NFLANK, CFLANK, NFPROX peptides, or the anti-pro-SP-C-antibody NPRO-SP-C-C2 and displaced by the respective peptide, were identified. Differences in the frequency of bands of all the disease groups were evaluated by the Fisher exact test and those with a P < 0.05 were indicated by an * for comparison with the healthy control group or by a + for comparison with the disease control group, bronchitis (see table 2). §indicates a significant difference to the disease control group, bronchitis, when all NFPROX reactive bands were combined (P < 0.01). The identification numbers of the patients are given in square brackets []. Numbers in bold indicate bands not identified by the CTERMB antibodies.
